Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer

Human Immunology

Volumn 73, Issue 6, 2012, Pages 668-672

  Guirado, Macarena ^a   Gil, Hernani ^b   Saenz Lopez, Pablo ^a,b   Reinboth, Jennifer ^c   Garrido, Federico ^a,b   Cozar, José Manuel ^b   Ruiz Cabello, Francisco ^b   Carretero, Rafael ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c GENELUX CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C13ORF31 PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; PROTEIN; RECEPTOR INTERACTING SERINE THREONINE PROTEIN KINASE 2; TOLL LIKE RECEPTOR 10; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; RISK; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 10; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84861765474     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.03.006     Document Type: Article

References (38)

1. Jacobs B.L., Lee C.T., Montie J.E. Bladder cancer in 2010: how far have we come?. CA Cancer J Clin 2010, 60:244.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Hirao Y., Kim W.J., Fujimoto K. Environmental factors promoting bladder cancer. Curr Opin Urol 2009, 19:494.
4. Oh S.S., Chang S.C., Cai L., Cordon-Cardo C., Ding B.G., Greenland S., et al. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer 2010, 127:2169-2182.
5. Colin P., Koenig P., Ouzzane A., et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009, 104:1436.
6. Yang H., Gu J., Lin X., Grossman H.B., Ye Y., Dinney C.P., Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 2008, 14:2236-2244.
7. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 2010, 10:369.
8. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211.
9. Ahirwar D.K., Agrahari A., Mandhani A., et al. Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 2009, 14:213.
10. Sáenz-López P., Carretero R., Cózar J.M., Romero J.M., Canton J., Vilchez J.R., et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 2008, 8:382.
11. Sáenz-López P., Carretero R., Vazquez F., Martin J., Sánchez E., Tallada M., et al. Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol 2010, 71:309.
12. Romero J.M., Sáenz-López P., Cózar J.M., Carretero R., Canton J., Vazquez F., et al. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol 2009, 70:60.
13. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009, 227:221.
14. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805.
15. Kufer T., Banks D., Philpott D. Innate immune sensing of microbes by Nod proteins. Ann NY Acad Sci 2006, 1072:19.
16. Kobayashi K., Inohara N., Hernandez L.D., Galán J.E., Núñez G., Janeway C.A., et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002, 416:194.
17. Solomon E.I., Sundaram U.M., Machonkin T.E. Multicopper oxidases and oxygenases. Chem Rev 1996, 96:25-63.
18. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955.
19. Zhang F.R., Huang W., Chen S.M., Sun L.D., Liu H., Li Y., et al. Genomewide association study of leprosy. New Engl J Med 2009, 361:2609.
20. Karin M., Greten F.R. NF-κB linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749.
21. Rothman N., Garcia-Closas M., Chatterjee N., Malats N., Wu X., Figueroa J.D., et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010, 42:978.
22. Rakoff-Nahoum S., Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) 2008, 73:555.
23. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
24. Bui J.D., Schreiber R.D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol 2007, 19:203.
25. Miyazaki J., Kawai K., Oikawa T., Johraku A., Hattori K., Shimazui T., et al. Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signaling. BJU Int 2006, 97:860.
26. Sexton W.J., Wiegand L.R., Correa J.J., Politis C., Dickinson S.I., Kang L.C. Bladder cancer: a review of non-muscle invasive disease. Cancer Control 2010, 17:256.
27. Stevens V.L., Hsing A.W., Talbot J.T., Zheng S.L., Sun J., Chen J., et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer 2008, 123:2644.
28. Zhou X.X., Jia W.H., Shen G.P., Qin H.D., Yu X.J., Chen L.Z., et al. Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev 2006, 15:862.
29. Freire P., Portela F., Donato M.M., Figueiredo P., Ferreira M., Amaro P., et al. CARD15 mutations and colorectal cancer in a South European country. Int J Colorectal Dis 2010, 25:1211.
30. Wex T., Ebert M.P., Kropf S., Dierkes J., Schüttler K., Röcken C., et al. Gene polymorphisms of the NOD-2/CARD-15 gene and the risk of gastric cancer in Germany. Anticancer Res 2008, 28:757.
31. Pandey A.K., Yang Y., Jiang Z., Fortune S.M., Coulombe F., Behr M.A., et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog 2009, 5:e1000500.
32. Thiébaut R., Douchin V., Jung C., Merlin F., Colombel J.F., Lemann M., et al. RIP2 polymorphisms in inflammatory bowel diseases. Inflamm Bowel Dis 2011, 17(4):1055. 10.1002/ibd.21406.
33. Nakashima K., Hirota T., Suzuki Y., Akahoshi M., Shimizu M., Jodo A., et al. Association of the RIP2 gene with childhood atopic asthma. Allergol Int 2006, 55(1):77-83.
34. Bolli A., Galluzzo P., Ascenzi P., Del Pozzo G., Manco I., Vietri M.T., et al. Laccase treatment impairs bisphenol A-induced cancer cell proliferation affecting estrogen receptor alpha-dependent rapid signals. IUBMB Life 2008, 60:843.
35. Keri R.A., Ho S.M., Hunt P.A., Knudsen K.E., Soto A.M., Prins G.S. An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol 2007, 24:240.
36. Andrew A.S., Gui J., Sanderson A.C., Mason R.A., Morlock E.V., Schned A.R., et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet 2009, 125:527.
37. Tetu B. Diagnosis of urothelial bladder cancer. Modern Pathol 2009, 22:S53-S59.
38. Sullivan P.S., Chan J.B., Levin M.R., Rao J. Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res 2010, 2:412-440.